InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomessignificantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.

AI/ML

Biotechnology

Health Care

InterVenn Biosciences

Barbara Weaver

Daniel Hommes

Alex Lindell

Kenneth Bryan Piamonte

Norton Kitagawa

Aimee Bosch, PMP

Janet Saliba, CPA - Inactive

Daniel Serie

Kaitlynn Moser

Xin Cong

Stephana Patton

InterVenn Biosciences

Org chart

Similar companies